A malaria vaccine for control: more progress.
نویسندگان
چکیده
Joel G. Breman and Christopher V. Plowe Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, and Howard Hughes Medical Institute and Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (See the article by Sacarlal et al, on pages 329–36, and the article by Kester et al, on pages 337–46.)
منابع مشابه
Malaria vaccine developments.
Large gains in the reduction of malaria mortality in the early 20th century were lost in subsequent decades. Malaria now kills 2-3 million people yearly. Implementation of malaria control technologies such as insecticide-treated bednets and chemotherapy could reduce mortality substantially, but an effective malaria vaccine is also needed. Advances in vaccine technology and immunology are being ...
متن کاملLife Cycle of Malaria Parasite and Vaccine Targets
Malaria is still one of the infectious diseases urgently requiring control and causes socioeconomic burdens on people residing in developing countries. Malaria vaccines are expected to control the disease. However, there is no effective vaccine available despite the intense efforts of malaria scientists. One strategy for a malaria vaccine is to prevent parasite spread by means of interfering wi...
متن کاملPrevention Efforts for Malaria
Purpose of Review Malaria remains a global burden contributing to morbidity and mortality especially in children under 5 years of age. Despite the progress achieved towards malaria burden reduction, achieving elimination in more countries remains a challenge. This article aims to review the prevention and control strategies for malaria, to assess their impact towards reducing the disease burden...
متن کاملOptimized Method for Purification of Expressed Plasmodium Vivax Duffy Binding Protein-II (PvDBP-II): Implication for Vivax Malaria Vaccine Development
Background: The purity and correct folding of a recombinant protein is critical for any structural, biochemical and vaccine design studies. Plasmodium vivax Duffy binding protein-II is a leading vaccine candidate for vivax malaria. In the present study, the purification process of recombinant DBP-IX (a variant form of PvDBP-II) was optimized to achieve the highest yield and purity. Moreover, ...
متن کاملMalaria battle boost
Microsoft founder, Bill Gates, pledged more than $160 million from his charitable foundation to help develop vaccines for malaria as part of a package of funds totalling $3 billion revealed at a meeting at the UN to assess progress in the Millennium Development Goals to halve global poverty by 2015. Gates said that his funds would be for the PATH Malaria Vaccine Initiative (MVI), in conjunction...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Journal of infectious diseases
دوره 200 3 شماره
صفحات -
تاریخ انتشار 2009